This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kowey, P. R. Search for Related Content PubMed PubMed Citation Articles by Kowey, P. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMIODARONE HYDROCHLORIDE CARVEDILOL DIGOXIN METOPROLOL Medline Plus Health Information Atrial Fibrillation Heart Failure Social Bookmarking                         What's this?

A Review of Carvedilol Arrhythmia Data in Clinical Trials

Division of Cardiovascular Diseases, Main Line Health Heart Center, Wynnewood, PA; and Department of Medicine, Jefferson Medical College, Philadelphia, PA

ß-Blockers are currently being evaluated more intensively to define their role in clinical use as antiarrhythmic agents. ß-Adrenergic blockade has been studied in relation to atrial fibrillation, ventricular arrhythmias, and sudden death; however, it is apparent from a number of studies that not all ß-blockers are equally effective. Randomized clinical trial data, both in heart failure and post-myocardial infarction (MI) patients, have shown differences in mortality benefits in addition to a variable effect on arrhythmias and sudden death. Carvedilol, a third-generation ß-blocker with proven clinical benefit in the management of heart failure and post-MI patients, has properties that may make it an effective antiarrhythmic agent. This paper reviews the current clinical arrhythmia data available for carvedilol from large-scale clinical trials and small studies. The trial evidence demonstrates that carvedilol therapy can be an effective adjunctive rate-control therapy in patients with atrial fibrillation, prevent mortality in patients with heart failure or post-MI with left ventricular dysfunction, with or without atrial fibrillation, and reduce its onset and the incidence of ventricular arrhythmia and sudden death.

Key Words: ß-blockers • atrial fibrillation • antiarrhythmics • carvedilo

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 10, No. 4 suppl, S59-S68 (2005)
DOI: 10.1177/10742484050100i407


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Fox, J. S. Borer, A. J. Camm, N. Danchin, R. Ferrari, J. L. Lopez Sendon, P. G. Steg, J.-C. Tardif, L. Tavazzi, M. Tendera, et al. Resting Heart Rate in Cardiovascular Disease J. Am. Coll. Cardiol., August 28, 2007; 50(9): 823 - 830. [Abstract] [Full Text] [PDF]

				B. N. Singh {beta}-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S3 - S14. [Abstract] [PDF]